Longer Hydroxyurea Administration Prior to Imatinib Mesylate Is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role

Asian Pacific Journal of Cancer Prevention
doi 10.31557/apjcp.2019.20.12.3689
Full Text
Abstract

Available in full text

Date
Authors
Publisher

EpiSmart Science Vector Ltd

Related search

Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia

Haematologica
Hematology
2010English

Reduced-Intensity Allogeneic Transplantation Combined With Imatinib Mesylate for Chronic Myeloid Leukemia in First Chronic Phase

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Epstein-Barr Virus-Associated Lymphoproliferative Disease During Imatinib Mesylate Treatment for Chronic Myeloid Leukemia

Haematologica
Hematology
2019English

Cost Effectiveness of Therapeutic Drug Monitoring for Imatinib Administration in Chronic Myeloid Leukemia

PLoS ONE
Multidisciplinary
2019English

Polycomb Genes Are Associated With Response to Imatinib in Chronic Myeloid Leukemia

Epigenomics
Cancer ResearchGenetics
2015English

Somatic Mutations Identified at Diagnosis by Exome Sequencing Can Predict Response to Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients

American Journal of Hematology
Hematology
2017English

Chromosomal Abnormalities in Philadelphia Chromosome Negative Metaphases Appearing During Imatinib Mesylate Therapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Blood
BiochemistryImmunologyCell BiologyHematology
2007English

Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

New Tool for Monitoring Molecular Response in Chronic Myeloid Leukemia.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy